Cardiovascular Atlas
About
Menu

Study starts

The date a registry gives for a study starting.

41 events of 208. A year or a month is never shown as a day, and a year-only date sorts below the dated events of that year. 11 are registry dates that the registry does not mark as reached, so each says so. Expected future events are on the calendar.

2021 1

  1. Study start WHO HEARTS evaluation in Bangladesh

    Source: HEARTS Package Evaluation Trial in Bangladesh

2020 1

  1. Study start SURPASS-CVOT: tirzepatide against dulaglutide on major cardiovascular events

    Source: A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

2019 3

  1. Study start TRILUMINATE Pivotal trial

    Source: TRILUMINATE Pivotal Trial

  2. Study start FLOW: semaglutide and kidney outcomes in type 2 diabetes with chronic kidney disease

    Source: A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  3. Study start EMPA-KIDNEY: empagliflozin in a broad range of chronic kidney disease

    Source: EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

2018 3

  1. Study start ORION-4 (inclisiran outcome trial)

    Source: A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

  2. Study start SELECT: semaglutide and cardiovascular outcomes in overweight or obesity

    Source: Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

  3. Study start DELIVER

    Source: Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

2017 7

  1. Study start Apple Heart Study

    Source: Apple Heart Study: Assessment of Wristwatch-Based Photoplethysmography to Identify Cardiac Arrhythmias

  2. Study start TTM2

    Source: Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest

  3. Study start EARLY TAVR

    Source: EARLY TAVR: Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis

  4. Study start EMPEROR-Reduced

    Source: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

  5. Study start EMPEROR-Preserved

    Source: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

  6. Study start DAPA-HF

    Source: Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

  7. Study start DAPA-CKD: dapagliflozin in chronic kidney disease

    Source: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

2016 4

  1. Study start CLEAR Outcomes (bempedoic acid in statin-intolerant people)

    Source: Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

  2. Study start SECURE Registry does not say if reached

    Source: Secondary Prevention of Cardiovascular Disease in the Elderly Trial

  3. Study start Evolut Low Risk trial Registry does not say if reached

    Source: Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

  4. Study start PARTNER 3 trial

    Source: PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis

2015 1

  1. Study start FIDELIO-DKD: finerenone and kidney outcomes in type 2 diabetes

    Source: Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

2014 1

  1. Study start China Salt Substitute and Stroke Study (SSaSS)

    Source: China Salt Substitute and Stroke Study

2013 2

  1. Study start DECLARE-TIMI 58: dapagliflozin and cardiovascular outcomes in type 2 diabetes

    Source: Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

  2. Study start FOURIER (evolocumab in people with cardiovascular disease)

    Source: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

2012 3

  1. Study start ODYSSEY OUTCOMES (alirocumab after acute coronary syndrome)

    Source: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

  2. Study start COAPT trial

    Source: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) and COAPT CAS

  3. Study start ISCHEMIA (initial invasive or conservative strategy for stable coronary disease) Registry does not say if reached

    Source: International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

2010 3

  1. Study start Systolic Blood Pressure Intervention Trial (SPRINT)

    Source: Systolic Blood Pressure Intervention Trial (SPRINT)

  2. Study start LEADER: liraglutide and cardiovascular events in type 2 diabetes

    Source: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

  3. Study start EMPA-REG OUTCOME: empagliflozin and cardiovascular outcomes in type 2 diabetes Registry does not say if reached

    Source: BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

2009 1

  1. Study start PARADIGM-HF Registry does not say if reached

    Source: This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

2008 1

  1. Study start DANISH

    Source: Danish ICD Study in Patients With Dilated Cardiomyopathy

2007 1

  1. Study start CHAMPION trial Registry does not say if reached

    Source: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients

2006 2

  1. Study start ARISTOTLE

    Source: Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE)

  2. Study start ROCKET AF Registry does not say if reached

    Source: An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation (ROCKET AF)

2005 3

  1. Study start RE-LY

    Source: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

  2. Study start IMPROVE-IT (ezetimibe added to simvastatin after acute coronary syndrome)

    Source: IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)

  3. Study start PROTECT AF Registry does not say if reached

    Source: WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF)

2003 1

  1. Study start HF-ACTION Registry does not say if reached

    Source: Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure

2001 1

  1. Study start Look AHEAD: intensive lifestyle intervention in type 2 diabetes

    Source: Look AHEAD: Action for Health in Diabetes

1997 2

  1. Study start SCD-HeFT Registry does not say if reached

    Source: Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)

  2. Study start DASH-Sodium Registry does not say if reached

    Source: Dietary Patterns, Sodium Intake and Blood Pressure (DASH - Sodium)